NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD Inc (NASDAQ:TXMD) issued its earnings results on Thursday, February, 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. The firm had revenue of $15.90 million for the quarter, compared to analysts' expectations of $12.82 million. TherapeuticsMD had a negative net margin of 354.79% and a negative return on equity of 1,170.63%. The business's revenue was up 212.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) earnings per share. View TherapeuticsMD's Earnings History.

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for TherapeuticsMD.

TherapeuticsMD updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $90-110 million, compared to the consensus revenue estimate of $100.15 million.

9 Wall Street analysts have issued 1-year price objectives for TherapeuticsMD's stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate TherapeuticsMD's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 442.2% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

Media coverage about TXMD stock has trended positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. TherapeuticsMD earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for TherapeuticsMD.

TherapeuticsMD saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 90,930,000 shares, an increase of 6.5% from the January 30th total of 85,400,000 shares. Based on an average daily volume of 3,530,000 shares, the short-interest ratio is presently 25.8 days. Currently, 38.4% of the company's shares are short sold. View TherapeuticsMD's Current Options Chain.

Some companies that are related to TherapeuticsMD include Ligand Pharmaceuticals (LGND), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), BELLUS Health (BLUSF), Akcea Therapeutics (AKCA), Tricida (TCDA), Heron Therapeutics (HRTX), Aimmune Therapeutics (AIMT), Arvinas (ARVN), IGM Biosciences (IGMS), Zymeworks (ZYME), Alder Biopharmaceuticals (ALDR), Esperion Therapeutics (ESPR), Corcept Therapeutics (CORT) and Constellation Pharmaceuticals (CNST).

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), NVIDIA (NVDA), Horizon Therapeutics (HZNP), Inovio Pharmaceuticals (INO), Global Blood Therapeutics (GBT) and Micron Technology (MU).

TherapeuticsMD's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (6.52%), Bank of New York Mellon Corp (4.84%), Franklin Resources Inc. (3.50%), State Street Corp (2.04%), Bamco Inc. NY (1.41%) and Stifel Financial Corp (1.11%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

TXMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, FMR LLC, Franklin Resources Inc., Sanders Morris Harris LLC, SG Americas Securities LLC, Raymond James & Associates and First Eagle Investment Management LLC. View Insider Buying and Selling for TherapeuticsMD.

TXMD stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Marshall Wace North America L.P., State Street Corp, Knights of Columbus Asset Advisors LLC, Goldman Sachs Group Inc., Hawk Ridge Capital Management LP and Stifel Financial Corp. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $1.66.

TherapeuticsMD has a market capitalization of $450.73 million and generates $49.65 million in revenue each year. The company earns $-176,150,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]